An update on clinical trials of targeted therapies in thyroid cancer | Zendy

Sigurdís Haraldsdóttir | Zendy; Manisha H. Shah | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

An update on clinical trials of targeted therapies in thyroid cancer

Author(s) -

Sigurdís Haraldsdóttir,

Manisha H. Shah

Publication year - 2013

Publication title -

current opinion in oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.297

H-Index - 95

eISSN - 1080-8140

pISSN - 1040-8746

DOI - 10.1097/cco.0000000000000029

Subject(s) - medicine , vandetanib , cabozantinib , sorafenib , thyroid cancer , medullary thyroid cancer , targeted therapy , clinical trial , oncology , adverse effect , cancer , hepatocellular carcinoma

Several new targeted therapies with multikinase inhibitors targeting vascular endothelial growth factor (VEGF), rearranged during transfection and v-raf murine sarcoma viral oncogene homolog B1 pathways have been tested in clinical trials for radioiodine-refractory differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC) in the past 10 years.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research